We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Genomic Health Posts Impressive Data for Oncotype DX Test
Read MoreHide Full Article
Leading genomic-based diagnostic test services provider Genomic Health Inc. recently unveiled positive findings of its Oncotype DX test from various studies in individualizing breast cancer treatment decisions for patients at various stages of the disease. This development is part of the company’s consistent effort to progress in its Oncotype DX breast cancer test business.
In the majority of last six months, Genomic Health outpaced the Zacks categorized Medical-Biomed/Genetics sub-industry’s growth. Despite a disappointing third-quarter 2016 performance, Genomic Health’s share price movement remains strong. Over the past six months, the company gained 21.4%, whereas the Medical-Biomed/Genetics sub-industry declined 6.1%. Genomic Health also recorded a five-CAGR of 8.6% for revenues, reflecting strong its fundamentals. In spite of the company experiencing escalating cost of sales, its gross margin improved in the third quarter. We expect the recent findings of the Oncotype DX test to further boost the company’s share price return in the near term.
The Oncotype DX portfolio of breast, colon and prostate cancer assays applies advanced genomic science to evaluate the unique biology of a tumor in order to optimize cancer treatment. The company's flagship Oncotype DX breast cancer test has shown likelihood of chemotherapy benefit as well as prediction of probable recurrence of invasive breast cancer.
The latest studies of Oncotype DX test included double indications of prospective data and clinical evidence supporting use of the test in early-stage breast cancer patients with node-positive and node-negative diseases. Data also included new reports from the Surveillance, Epidemiology and End Results (SEER) Registry program of the National Cancer Institute (NCI), analyzing outcomes without chemotherapy and clinical utility of the Breast Recurrence Score (RS) in patients with high-grade tumors. There were also evidences from a clinical evaluation of the Breast DCIS Score in patients with ductal carcinoma in situ (DCIS).
Management claims that favorable data generated by independent researchers highlights the accuracy of Oncotype DX in predicting clinical outcomes and its unique value in providing physicians with critical genomic intelligence to enhance breast cancer treatment decisions and patient benefit. The latest Oncotype DX presentations are expected to help the clinicians understand breast cancer biology across the continuum of the disease.
As per a Market Research Store report, the global cancer diagnostics test is poised to reach $128.6 billion in 2020, growing at a CAGR of 7.6% between 2015 and 2020. Currently, Genomic Health is trying to strengthen its foothold in this arena along with its closest peer Myriad Genetics.
In the recently concluded third-quarter, Genomic Health delivered more than 29,990 Oncotype DX test results, up 8% year over year. We can say that Genomic Health is seeing meaningful progress in its cancer test businesses. The company’s Oncotype DX breast cancer test prospects are helping physicians take prompt treatment decisions. Management believes that an increase in adoption and reimbursement in breast cancer tests should deliver growth beyond Genomic Health’s profitable U.S. invasive breast cancer business.
Zacks Rank & Key Picks
Genomic Healthcarries a Zacks Rank #3 (Hold). Some well-ranked medical stocks are NxStage Medical Inc. , Baxter International Inc. (BAX - Free Report) and Bovie Medical Corporation . NxStage Medical and Baxter International sport a Zacks Rank #1 (Strong Buy), while Bovie Medical carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
NxStage Medical surged 33.8% over the last one year compared with the S&P 500’s 12.3% over the same period. The company has a four-quarter average positive earnings surprise of 46.3%.
Baxter International rallied 21.7% over the last one year, much higher than the S&P 500. It has a trailing four-quarter average positive earnings surprise of 27%.
Bovie Medical recorded a 125.5% gain in the past one year, way better than the S&P 500. The company has a trailing four-quarter positive average earnings surprise of 28.7%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Genomic Health Posts Impressive Data for Oncotype DX Test
Leading genomic-based diagnostic test services provider Genomic Health Inc. recently unveiled positive findings of its Oncotype DX test from various studies in individualizing breast cancer treatment decisions for patients at various stages of the disease. This development is part of the company’s consistent effort to progress in its Oncotype DX breast cancer test business.
In the majority of last six months, Genomic Health outpaced the Zacks categorized Medical-Biomed/Genetics sub-industry’s growth. Despite a disappointing third-quarter 2016 performance, Genomic Health’s share price movement remains strong. Over the past six months, the company gained 21.4%, whereas the Medical-Biomed/Genetics sub-industry declined 6.1%. Genomic Health also recorded a five-CAGR of 8.6% for revenues, reflecting strong its fundamentals. In spite of the company experiencing escalating cost of sales, its gross margin improved in the third quarter. We expect the recent findings of the Oncotype DX test to further boost the company’s share price return in the near term.
The Oncotype DX portfolio of breast, colon and prostate cancer assays applies advanced genomic science to evaluate the unique biology of a tumor in order to optimize cancer treatment. The company's flagship Oncotype DX breast cancer test has shown likelihood of chemotherapy benefit as well as prediction of probable recurrence of invasive breast cancer.
The latest studies of Oncotype DX test included double indications of prospective data and clinical evidence supporting use of the test in early-stage breast cancer patients with node-positive and node-negative diseases. Data also included new reports from the Surveillance, Epidemiology and End Results (SEER) Registry program of the National Cancer Institute (NCI), analyzing outcomes without chemotherapy and clinical utility of the Breast Recurrence Score (RS) in patients with high-grade tumors. There were also evidences from a clinical evaluation of the Breast DCIS Score in patients with ductal carcinoma in situ (DCIS).
GENOMIC HEALTH Price
GENOMIC HEALTH Price | GENOMIC HEALTH Quote
Management claims that favorable data generated by independent researchers highlights the accuracy of Oncotype DX in predicting clinical outcomes and its unique value in providing physicians with critical genomic intelligence to enhance breast cancer treatment decisions and patient benefit. The latest Oncotype DX presentations are expected to help the clinicians understand breast cancer biology across the continuum of the disease.
As per a Market Research Store report, the global cancer diagnostics test is poised to reach $128.6 billion in 2020, growing at a CAGR of 7.6% between 2015 and 2020. Currently, Genomic Health is trying to strengthen its foothold in this arena along with its closest peer Myriad Genetics.
In the recently concluded third-quarter, Genomic Health delivered more than 29,990 Oncotype DX test results, up 8% year over year. We can say that Genomic Health is seeing meaningful progress in its cancer test businesses. The company’s Oncotype DX breast cancer test prospects are helping physicians take prompt treatment decisions. Management believes that an increase in adoption and reimbursement in breast cancer tests should deliver growth beyond Genomic Health’s profitable U.S. invasive breast cancer business.
Zacks Rank & Key Picks
Genomic Healthcarries a Zacks Rank #3 (Hold). Some well-ranked medical stocks are NxStage Medical Inc. , Baxter International Inc. (BAX - Free Report) and Bovie Medical Corporation . NxStage Medical and Baxter International sport a Zacks Rank #1 (Strong Buy), while Bovie Medical carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
NxStage Medical surged 33.8% over the last one year compared with the S&P 500’s 12.3% over the same period. The company has a four-quarter average positive earnings surprise of 46.3%.
Baxter International rallied 21.7% over the last one year, much higher than the S&P 500. It has a trailing four-quarter average positive earnings surprise of 27%.
Bovie Medical recorded a 125.5% gain in the past one year, way better than the S&P 500. The company has a trailing four-quarter positive average earnings surprise of 28.7%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>